Research Letter
Combination of antitumour necrosis factor-α and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study
R. Gniadecki,
R. Gniadecki
Department of Dermatology D40, Bispebjerg Hospital, University of Copenhagen, Bispebjerg Bakke 23, 2400 Copenhagen, NV, Denmark
Search for more papers by this author B. Bang,
B. Bang
Department of Dermatology D40, Bispebjerg Hospital, University of Copenhagen, Bispebjerg Bakke 23, 2400 Copenhagen, NV, Denmark
Search for more papers by this author C. Sand,
C. Sand
Department of Dermatology D40, Bispebjerg Hospital, University of Copenhagen, Bispebjerg Bakke 23, 2400 Copenhagen, NV, Denmark
Search for more papers by this author
R. Gniadecki,
R. Gniadecki
Department of Dermatology D40, Bispebjerg Hospital, University of Copenhagen, Bispebjerg Bakke 23, 2400 Copenhagen, NV, Denmark
Search for more papers by this author B. Bang,
B. Bang
Department of Dermatology D40, Bispebjerg Hospital, University of Copenhagen, Bispebjerg Bakke 23, 2400 Copenhagen, NV, Denmark
Search for more papers by this author C. Sand,
C. Sand
Department of Dermatology D40, Bispebjerg Hospital, University of Copenhagen, Bispebjerg Bakke 23, 2400 Copenhagen, NV, Denmark
Search for more papers by this author
First published: 01 November 2015
No abstract is available for this article.
References
- 1Reich K, Burden AD, Eaton JN, Hawkins NS. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol 2012; 166: 179–88.
- 2Gniadecki R, Bang B, Bryld LE et al. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol 2015; 172: 244–52.
- 3Huynh D, Kavanaugh A. Psoriatic arthritis: current therapy and future approaches. Rheumatology (Oxford) 2015; 54: 20–8.
- 4Bendele A, Sennello G, McAbee T et al. Effects of interleukin 1 receptor antagonist alone and in combination with methotrexate in adjuvant arthritic rats. J Rheumatol 1999; 26: 1225–9.
- 5Bendele AM, Chlipala ES, Scherrer J et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 2000; 43: 2648–59.
- 6Genovese MC, Cohen S, Moreland L et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004; 50: 1412–19.
- 7Weinblatt M, Combe B, Covucci A et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 2006; 54: 2807–16.
- 8Weinblatt M, Schiff M, Goldman A et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 2007; 66: 228–34.
- 9Greenwald MW, Shergy WJ, Kaine JL et al. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial. Arthritis Rheum 2011; 63: 622–32.
- 10Nast A, Jacobs A, Rosumeck S, Werner RN. Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis – a systematic review and meta-analysis. J Invest Dermatol 2015; 135: 2641–8.
- 11Cuchacovich R, Garcia-Valladares I, Espinoza LR. Combination biologic treatment of refractory psoriasis and psoriatic arthritis. J Rheumatol 2012; 39: 187–93.
